THE ROLE OF EVOLVING TECHNIQUES AND PROSPECTIVE IMPLICATIONS OF BIOMARKERS IN LIVER DISEASE
Main Article Content
Keywords
Abstract
. Wounds that influence the liver are shockingly normal in more youthful individuals. This condition might introduce itself clinically as subclinical hepatitis, intense hepatitis, persistent hepatitis, remunerated liver constant infection, decompensated liver cirrhosis, intense liver disappointment, or intense on persistent liver disappointment. These indications are possible. A Liver Capability test would frequently take a gander at various different biochemical markers, including complete bilirubin, direct bilirubin, SGOT, SGPT, egg whites, supportive of thrombin time, and GGT. Novel biomarkers are presently effectively accessible as an immediate outcome of current specialized leap forwards and applications. The utilization of creature models is the beginning stage for the examination of these biomarkers, with the concentrate then, at that point, moving to human subjects. They can offer data that is demonstrative as well as data about the visualization. They give some enlightening data on the histological condition of the liver. Notwithstanding, they are restricted by the circumstances that they think of themselves as in. By directing an examination of marks of liver harm in youngsters, this exploration shows new conceivable outcomes and philosophies for the determination of liver sickness in kids. Concentrates on that focus on individual biomarkers as a restorative place of section are something that might be plausible to investigate not long from now. Hepatology is a subspecialty that is still during the time spent developing, and one of its subspecialties is the investigation of biomarkers. The developing weight of worldwide liver sickness, the shortfall of side effects until late in the regular history of an illness that might require a very long time to show, the presence of an obtrusive reference test (liver biopsy) to evaluate infection seriousness, and the absence of powerful instruments to survey the viability of restorative mediations are a portion of the critical drivers for this exploration. Furthermore, the shortfall of side effects until late in the regular history of a sickness that might require a very long time to show is one more key driver for this examination. Furthermore, one of the essential motivations behind why this study is being directed is because of the deficiency of dependable instruments with which to assess the viability of restorative methodologies.
Downloads
References
[1]. J. Atkinson, W. A. Colburn, V. G. DeGruttola et al., “Biomarkers and surrogate endpoints: preferred definitions and conceptual framework,” Clinical Pharmacology and Therapeutics, vol. 69, no. 3, pp. 89–95, 2001 [2]. D. Mildvan, A. Landay, V. de Gruttola, S. G. Machado, and J. Kagan, “An approach to the validation of markers for use in AIDS clinical trials,” Clinical Infectious Diseases, vol. 24, no. 5, pp. 764–774, 1997. [3]. J. Barr, M. Vazquez-Chantada, C. Alonso et al., “Liquid ´ chromatography—mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease,” Journal of Proteome Research, vol. 9, no. 9, pp. 4501–4512, 2010. [4]. P. Puri, M. M. Wiest, O. Cheung et al., “The plasma lipidomic signature of nonalcoholic steatohepatitis,” Hepatology, vol. 50, no. 6, pp. 1827–1838, 2009. [5]. L. N. Bell, J. L. Theodorakis, R. Vuppalanchi et al., “Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease,” Hepatology, vol. 51, no. 1, pp. 111–120, 2010. [6]. Z. M. Younossi, A. Baranova, K. Ziegler et al., “A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease,” Hepatology, vol. 42, no. 3, pp. 665–674, 2005. [7]. L. Castera, C. H ´ ezode, F. Roudot-Thoraval et al., “Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis,” Gut, vol. 53, no. 3, pp. 420– 424, 2004. [8]. M. R. Teli, O. F. W. James, A. D. Burt, M. K. Bennett, and C. P. Day, “The natural history of nonalcoholic fatty liver: a follow up study,” Hepatology, vol. 22, no. 6, pp. 1714–1719, 1995. [9]. C. Sooderberg, P. St ¨ al, J. Askling et al., “Decreased survival ˚ of subjects with elevated liver function tests during a 28-year follow-up,” Hepatology, vol. 51, no. 2, pp. 595–602, 2010. [10]. M. Yano, H. Kumada, M. Kage et al., “The long-term pathological evolution of chronic hepatitis C,” Hepatology, vol. 23, no. 6, pp. 1334–1340, 1996. [11]. T. Poynard, P. Bedossa, and P. Opolon, “Natural history of liver fibrosis progression in patients with chronic hepatitis C,” The Lancet, vol. 349, no. 9055, pp. 825–832, 1997. [12]. C. A. Matteoni, Z. M. Younossi, T. Gramlich, N. Boparai, Yao Chang Liu, and A. J. McCullough, “Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity,” Gastroenterology, vol. 116, no. 6, pp. 1413–1419, 1999. [13]. A. Lawson, S. Hagan, K. Rye et al., “The natural history of hepatitis C with severe hepatic fibrosis,” Journal of Hepatology, vol. 47, no. 1, pp. 37–45, 2007. [14]. L. Castera, “Noninvasive methods to assess liver disease in patients with hepatitis B or C,” Gastroenterology, vol. 142, no. 6, pp. 1293.e4–1302.e4, 2012. [15]. J. Parkes, I. N. Guha, P. Roderick et al., “Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C,” Journal of Viral Hepatitis, vol. 18, no. 1, pp. 23–31, 2011. [16]. Y. Ngo, M. Munteanu, D. Messous et al., “A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C,” Clinical Chemistry, vol. 52, no. 10, pp. 1887–1896, 2006. [17]. J. Vergniol, J. Foucher, E. Terrebonne et al., “Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C,” Gastroenterology, vol. 140, no. 7, pp. 1970.e3–1979.e3, 2011. [18]. D. Rincon, O. Lo Iacono, C. Ripoll et al., “Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 7, pp. 841–848, 2007. [19]. C. Ripoll, P. Lastra, D. Rincon, V. Catalina, and R. Ba ´ aares, ˜ “Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis,” Scandinavian Journal of Gastroenterology, vol. 47, no. 2, pp. 204–211, 2012. [20]. H. B. El-Serag, “Hepatocellular carcinoma,” The New England Journal of Medicine, vol. 365, no. 12, pp. 1118–1127, 2011. [21]. Forde, K.A.; Reddy, K.R. Hepatitis C Virus Infection and Immunomodulatory Therapies. Clin. Liver Dis. 2009, 13, 391–401. [CrossRef] [22]. Blachier, M.; Leleu, H.; Peck-Radosavljevic, M.; Valla, D.; Roudot-Thoraval, F. The burden of liver disease in Europe: A review of available epidemiological data. J. Hepatol. 2013, 58, 593–608. [CrossRef] [PubMed] [23]. Bansal, R.; Nagórniewicz, B.; Prakash, J. Clinical Advancements in the Targeted Therapies against Liver Fibrosis. Mediat. Inflamm. 2016, 2016, 1–16. [CrossRef] [PubMed] [24]. Goldberg, D.; Ditah, I.C.; Saeian, K.; Lalehzari, M.; Aronsohn, A.; Gorospe, E.C.; Charlton, M. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology 2017, 152, 1090–1099. [CrossRef] [PubMed] [25]. Du, C.; Jiang, M.; Wei, X.; Qin, J.; Xu, H.; Wang, Y.; Zhang, Y.; Zhou, D.; Xue, H.; Zheng, S.; et al. Transplantation of human matrix metalloproteinase-1 gene-modified bone marrow-derived mesenchymal stem cell attenuates CCL4-induced liver fibrosis in rats. Int. J. Mol. Med. 2018, 41, 3175–3184. [CrossRef] [26]. Fonovic, M.; Turk, B. Cysteine cathepsins and extracellular matrix degradation. Biochim. Biophys. Acta 2014, 1840, 2560–2570. [CrossRef] [27]. Binder, M.J.; McCoombe, S.; Williams, E.D.; McCulloch, D.; Ward, A. The extracellular matrix in cancer progression: Role of hyalectan proteoglycans and ADAMTS enzymes. Cancer Lett. 2017, 385, 55–64. [CrossRef] [28]. Lu, P.; Takai, K.; Weaver, V.M.; Werb, Z. Extracellular Matrix Degradation and Remodeling in Development and Disease. Cold Spring Harb. Perspect. Biol. 2011, 3, a005058. [CrossRef] [29]. Sternlicht, M.D.; Werb, Z. How Matrix Metalloproteinases Regulate Cell Behavior. Annu. Rev. Cell Dev. Biol. 2001, 17, 463–516. [CrossRef] [30]. Flannery, C.R. MMPs and ADAMTSs: Functional studies. Front. Biosci. 2006, 11, 544569. [CrossRef] [31]. Gross, J.; Lapière, C.M. Collagenolytic Activity in Amphibian Tissues: A Tissue Culture Assay. Proc. Natl. Acad. Sci. USA 1962, 48, 1014–1022. [CrossRef] [32]. Löffek, S.; Schilling, O.; Franzke, C.W. Series ‘matrix metalloproteinases in lung health and disease’ edited by J. Müller-Quernheim and O. Eickelberg number 1 in this series: Biological role of matrix metalloproteinases: A critical balance. Eur. Respir. J. 2011, 38, 191–208. [CrossRef] [PubMed] [33]. Chuang, H.-M.; Chen, Y.-S.; Harn, H.-J. The Versatile Role of Matrix Metalloproteinase for the Diverse Results of Fibrosis Treatment. Molecules 2019, 24, 4188. [CrossRef] [PubMed] [34]. Madzharova, E.; Kastl, P.; Sabino, F.M.R.; Keller, U.A.D. Post-Translational Modification-Dependent Activity of Matrix Metalloproteinases. Int. J. Mol. Sci. 2019, 20, 3077. [CrossRef] [PubMed] [35]. Cui, N.; Hu, M.; Khalil, R.A. Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog Mol Biol Transl Sci. 2017, 147, 1–73. [PubMed] [36]. Consolo, M.; Amoroso, A.; Spandidos, D.A.; Mazzarino, M.C. Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int. J. Mol. Med. 2009, 24, 143–152. [PubMed] [37]. Iredale, J. Tissue inhibitors of metalloproteinases in liver fibrosis. Int. J. Biochem. Cell Biol. 1997, 29, 43–54. [CrossRef] [38]. Roeb, E. Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol. 2018, 68–69, 463–473. [CrossRef] [39]. Murawaki, Y.; Ikuta, Y.; Idobe, Y.; Kawasaki, H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J. Gastroenterol. Hepatol. 2002, 14, 138–145. [CrossRef] [40]. Attallah, A.; El-Far, M.; Malak, C.A.A.; Omran, M.M.; Farid, K.; Hussien, M.A.; Albannan, M.; Attallah, A.; Elbendary, M.S.; Elbesh, D.A.; et al. Fibro-check: A combination of direct and indirect markers for liver fibrosis staging in chronic hepatitis C patients. Ann. Hepatol. 2015, 14, 225–233. [CrossRef] [41]. Ando, W.; Yokomori, H.; Tsutsui, N.; Yamanouchi, E.; Suzuki, Y.; Oda, M.; Inagaki, Y.; Otori, K.; Okazaki, I. Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. Clin. Mol. Hepatol. 2018, 24, 61–76. [CrossRef] [42]. Zhou, Z.; Ma, X.; Wang, F.-M.; Sun, L.; Zhang, G. A Matrix Metalloproteinase-1 Polymorphism, MMP1–1607 (1G>2G), Is Associated with Increased Cancer Risk: A Meta-Analysis Including 21,327 Patients. Dis. Markers 2018, 2018, 1–12. [CrossRef] [PubMed] [43]. Iimuro, Y.; Nishio, T.; Morimoto, T.; Nitta, T.; Stefanovic, B.; Choi, S.K.; Brenner, D.A.; Yamaoka, Y. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterol. 2003, 124, 445–458. [CrossRef] [PubMed] [44]. Takahara, T.; Furui, K.; Yata, Y.; Jin, B.; Zhang, L.P.; Nambu, S.; Sato, H.; Seiki, M.; Watanabe, A. Dual!expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 1997, 26, 1521–1599. [CrossRef] [PubMed] [45]. Lichtinghagen, R.; Bahr, M.J.; Wehmeier, M.; Michels, D.; Haberkorn, C.I.; Arndt, B.; Flemming, P.; Manns, M.P.; Boeker, K.H.W. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin. Sci. 2003, 105, 373–382. [CrossRef] [PubMed] [46]. Huang, C.-C.; Chuang, J.-H.; Chou, M.-H.; Wu, C.-L.; Chen, C.-M.; Wang, C.-C.; Chen, Y.-S.; Chen, C.-L.; Tai, M.-H. Matrilysin (MMP-7) is a major matrix metalloproteinase upregulated in biliary atresia-associated liver fibrosis. Mod. Pathol. 2005, 18, 941–950. [CrossRef] [47]. Cursio, R.; Mari, B.; Louis, K.; Rostagno, P.; Saint-Paul, M.-C.; Giudicelli, J.; Bottero, V.; Anglard, P.; Yiotakis, A.; Dive, V.; et al. Rat liver injury following normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J. 2002, 16, 93–95. [CrossRef] [48]. Prystupa, A.; Boguszewska-Czubara, A.; Bojarska-Junak, A.; Toru ´n-Jurkowska, A.; Roli ´nski, J.; Załuska, W.; Załuska, W. Activity of MMP-2, MMP-8 and MMP-9 in serum as a marker of progression of alcoholic liver disease in people from Lublin Region, eastern Poland. Ann. Agric. Environ. Med. 2015, 22, 325–328. [CrossRef] [49]. Radbill, B.D.; Gupta, R.; Ramirez, M.C.M.; DiFeo, A.; Martignetti, J.A.; Alvarez, C.E.; Friedman, S.L.; Narla, G.; Vrabie, R.; Bowles, R.; et al. Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin-Induced Liver Fibrosis by Upregulating Collagen I Expression. Dig. Dis. Sci. 2011, 56, 406–416. [CrossRef] [50]. Onozuka, I.; Kakinuma, S.; Kamiya, A.; Miyoshi, M.; Sakamoto, N.; Kiyohashi, K.; Watanabe, T.; Funaoka, Y.; Ueyama, M.; Nakagawa, M.; et al. Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. Biochem. Biophys. Res. Commun. 2011, 406, 134–140. [CrossRef] [51]. Bodey, B.; Bodey, B., Jr.; Siegel, S.E.; Kaiser, H.E. Immunocytochemical detection of MMP-3 and -10 expression in hepatocellular carcinomas. Anticancer. Res. 2000, 20, 4585–4590. [52]. Okamoto, K.; Mandai, M.; Mimura, K.; Murawaki, Y.; Yuasa, I. The association of MMP-1, -3 and -9 genotypes with the prognosis of HCV-related hepatocellular carcinoma patients. Res. Commun. Mol. Pathol. Pharmacol. 2005, 117-118, 77–89. [PubMed]
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.